ESR1 and breast carcinoma: All three trial programs, PALOMA (1, 2, 3), MONALEESA (2, 3, 7), and MONARCH (1, 2, 3), showed significant improvement in PFS amongst advanced ER+/HER2− breast cancer patients across all menopausal statuses; however, there were some key differences.